- Israel says conducting review after UN peacekeepers wounded in Lebanon
- 'Party atmosphere': Skygazers treated to another aurora show
- Djokovic 'overwhelmed' after 'greatest rival' Nadal's retirement
- Zelensky in Berlin says hopes war with Russia will end next year
- Kyrgyzstan opens rare probe into glacier destruction
- European Mediterranean states discuss Middle East, migration
- Djokovic proves staying power as progresses to Shanghai semi-finals
- Hurricane Milton leaves at least 16 dead as Florida cleans up
- Britain face 'ultimate challenge' in America's Cup duel with New Zealand
- Lebanon calls for 'immediate' ceasefire in Israel-Hezbollah war
- Nihon Hidankyo: Japan's A-bomb survivors awarded Nobel
- Thunberg leads pro-Palestinian, climate protest in Milan
- Boat captain rescued clinging to cooler in Gulf of Mexico after storm Milton
- Tears, warnings after Japan atomic survivors group win Nobel
- 'Unspeakable horror': the attacks on Hiroshima and Nagasaki
- Stock markets diverge before China weekend briefing
- Christian villagers 'trapped' in south Lebanon crossfire
- Sabalenka sets up Gauff showdown in Wuhan semis
- EU questions shopping app Temu over illegal products risk
- Kim Sei-young holds lead with late birdies at LPGA Shanghai
- Toulouse welcome Dupont 'boost' as Olympic star returns to Top 14
- Japanese atomic bomb survivor group Nihon Hidankyo wins Nobel Peace Prize
- Deadly Israeli strike on Beirut likely targeted Hezbollah security chief
- Bangladesh Islamist chief backs crimes against humanity trial for ex-PM
- Everest climber's remains believed found after 100 years
- 20 Pakistan coal miners shot dead in attack
- Clashes on South China Sea, Ukraine dominate Asia summit
- Han Kang's books sell out in South Korea after Nobel win
- Zelensky meets Pope, Scholz as whirlwind Europe tour ends
- Hello Hallyu: why is South Korean culture sweeping the globe?
- UK economy rebounds in August in boost to new govt
- Voice of Japan's beloved robot cat 'Doraemon' dies
- Shanghai markets sink ahead of briefing on mixed day for Asia
- Investors, analysts eye bigger China stimulus at Saturday briefing
- 20 Pakistan coal miners shot dead in attack: police
- Blinken condemns China's 'increasingly dangerous' sea moves
- Toyota returns to Formula One as Haas partner
- EU chief says China must 'adapt its behaviour' to solve trade row
- Musk unveils robotaxi, pledges it 'before 2027'
- Lynx rally, stun Liberty in overtime in WNBA Finals opener
- Pogacar hunting 'perfect' season finale with Coppi's Il Lombardia record
- 'Soul of old Baghdad': city centre sees timid revival
- Kittle at the double as Niners hold off Seahawks
- At least 11 dead in Florida but Hurricane Milton not as bad as feared
- Yankees advance in MLB playoffs as Guardians stay alive
- Asian markets mixed after Wall St drop, Shanghai dips before briefing
- Automaker Stellantis says CEO will retire in 2026
- Musk's promised robotaxi unveil delayed
- Kamada says Japan can close in on World Cup place against Australia
- On US coast, wind power foes embrace 'Save the Whales' argument
RBGPF | -1.03% | 59.49 | $ | |
RYCEF | 0.58% | 6.92 | $ | |
BCC | 1.98% | 141.755 | $ | |
SCS | 2.48% | 12.92 | $ | |
VOD | -0.83% | 9.66 | $ | |
RIO | 0.42% | 67.12 | $ | |
NGG | 0.84% | 66.235 | $ | |
CMSC | -0.14% | 24.555 | $ | |
JRI | 0.11% | 13.235 | $ | |
GSK | -1.06% | 38.8 | $ | |
RELX | 1.44% | 47.035 | $ | |
CMSD | 0.12% | 24.8 | $ | |
BCE | 0.2% | 32.925 | $ | |
BP | -0.61% | 32.145 | $ | |
AZN | 0.3% | 77.105 | $ | |
BTI | -0.07% | 35.085 | $ |
New weight loss pill more effective than Ozempic: Novo Nordisk
An experimental new weight loss pill from Danish pharmaceutical giant Novo Nordisk could be twice as effective as its blockbuster Ozempic and Wegovy jabs, early results from a small trial have suggested, sending the firm's shares soaring.
The drug amycretin caused people to lose 13 percent of their body weight over three months, according to the results of a phase one trial announced by the company.
Previous trials have found that Novo Nordisk's Ozempic and Wegovy drugs lead to around six percent body weight loss over the same period.
However experts emphasised that significantly more research was needed to establish the long-term effectiveness and safety of amycretin.
Nonetheless, the announcement at an investor event on Thursday sent Novo Nordisk's shares shooting up more than eight percent.
The immense popularity of this new generation of drugs called GLP-1 agonists have already made Novo Nordisk Europe's most valuable company, even as overwhelming demand has sparked major stock shortages.
Unlike other semaglutide drugs such as Ozempic, Wegovy and US firm's Mounjaro, amycretin was taken as a pill, rather than a once-weekly injection.
Similar to those drugs, amycretin mimics the appetite-reducing gut hormone GLP-1.
But it also mimics another hormone called amylin.
"This approach seems to be a little bit more exciting, from the limited data that we have," Daniel Drucker, a researcher at the Canada's University of Toronto, told New Scientist.
But far more data was needed, he said, adding that amycretin has not been directly compared to other drugs in a head-to-head trial.
Novo Nordisk's executive vice president for development Martin Holst Lange told the investor event that amycretin has the "potential of showing the same efficacy and safety as CagriSema," another of the firm's GLP-1 agonist drugs which targets amylin.
The results from a trial of an injectable form of amycretin are expected at some point next year, he said. The firm would then look into an "ambitious further development programme," he added.
For the amycretin trial, which involved 16 people with an average weight of 89 kilograms, those given a placebo lost one percent of their body weight over 12 weeks.
GLP-1 agonists have been found to cut the risk of cardiovascular disease associated with obesity -- but they also heighten the risk of gastrointestinal problems, studies show.
Research has also demonstrated that once people stop taking the drugs, they largely regain the weight they had lost.
M.Thompson--AMWN